Press Release: New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

Novartis

109.50 EUR 2.34%

• Charts
• News
• Analysen

Kaufen Verkaufen

-- Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment

pattern data, and zigakibart Phase I/II trial showcase strength of IgA

nephropathy (IgAN) portfolio

-- C3 glomerulopathy (C3G) studies add to body of evidence of Fabhalta

long-term safety and efficacy profile in native and post-transplant

disease recurrence patients

-- V-INCEPTION analyses highlight Leqvio adherence and goal attainment data

when initiated early in post-acute coronary syndrome patients

-- Lp(a) data underscore importance of early detection of this independent

CVD risk factor in premature ASCVD patients and potential benefit of

Lp(a)-targeted therapies

Basel, November 4, 2025 -- Novartis will present new data from 33 abstracts across its Cardiovascular, Renal, and Metabolic (CRM) disease portfolio at the upcoming American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas and American Heart Association's (AHA) Scientific Sessions 2025 in New Orleans, Louisiana, advancing scientific insight into these critical disease areas.

"Novartis will present a broad range of data at ASN and AHA demonstrating innovation and commitment to advancing therapies that address root causes of heart and kidney conditions," said Ruchira Glaser, M.D., Global Head, Cardiovascular, Renal and Metabolic Development Unit, Novartis. "Studies on both our approved and investigational therapies in these closely connected therapeutic areas reflect our longstanding dedication to deliver meaningful solutions for patients living with some of the rarest to most prevalent CRM diseases worldwide."

Key highlights of data accepted by ASN include:

Abstract Title Abstract Number/Presentation Details

Fabhalta(R) (iptacopan)

------------------------------------------------------------ ------------------------------------

Efficacy and Safety of Iptacopan in Patients (Pts) Abstract #PO0811

from East Asia with IgAN: Interim Results from the Poster Presentation

Phase 3 APPLAUSE-IgAN Trial November 7, 10:00 AM -- 12:00 PM CT

------------------------------------------------------------ ------------------------------------

Early Insights into Characteristics and Treatment Abstract #PO0771

Patterns of US Patients (Pts) with IgAN Who Were Prescribed Poster Presentation

Iptacopan: The APPRISE-IgAN Data Platform November 8, 10:00 AM -- 12:00 PM CT

------------------------------------------------------------ ------------------------------------

Efficacy and Safety of Iptacopan in Patients with Abstract #PO0838

C3 Glomerulopathy: C3G Extension Trial Interim Results Poster Presentation

from the Phase 3 APPEAR-C3G Patients November 7, 10:00 AM -- 12:00 PM CT

------------------------------------------------------------ ------------------------------------

Update to the Long-Term Efficacy and Safety of Iptacopan Abstract #PO0837

in C3 Glomerulopathy: 39-Month Phase 2 Extension Study Poster Presentation

Data November 7, 10:00 AM -- 12:00 PM CT

------------------------------------------------------------ ------------------------------------

Iptacopan Treatment in Patients with C3 Glomerulopathy Abstract #PO0811

(C3G): 12-Month Results from the Early Access Program Poster Presentation

November 8, 10:00 AM -- 12:00 PM CT

------------------------------------------------------------ ------------------------------------

Vanrafia(R) (atrasentan)

------------------------------------------------------------ ------------------------------------

Renin-Angiotensin System Inhibitor (RASi) Use and Abstract #PO0827

Atrasentan in IgAN: Post Hoc Analysis from the ALIGN Poster Presentation

Trial November 7, 10:00 AM -- 12:00 PM CT

------------------------------------------------------------ ------------------------------------

Efficacy and Safety of Atrasentan in Patients (Pts) Abstract #OR034

with IgAN from East (E) Asia: Phase 3 ALIGN Interim Oral Presentation

Data November 7, 5:30 -- 5:40 PM CT

------------------------------------------------------------ ------------------------------------

Zigakibart

------------------------------------------------------------ ------------------------------------

Long-Term Stabilization of Kidney Function Regardless Abstract #PO0814

of Baseline eGFR and Urine Protein-to-Creatinine Ratio Poster Presentation

(UPCR) in Patients with IgAN: Subgroup Analyses from November 7, 10:00 AM -- 12:00 PM CT

the Phase 1/2 Trial of Zigakibart

------------------------------------------------------------ ------------------------------------

SHIFT: A Kidney Biopsy Study in Adults with IgAN Treated Abstract #INFO18

with Zigakibart Informational Poster

November 7, 10:00 AM -- 12:00 PM CT

------------------------------------------------------------ ------------------------------------

Farabursen

----------------------------------------------------------------------------------------------------

Farabursen Increases Urinary Polycystin-1 and Polycystin-2 Abstract #OR089

and Reduces Height-Adjusted Total Kidney Volume Growth Oral Presentation

in Patients with ADPKD November 8, 4:30 PM -- 6:00 PM CT

------------------------------------------------------------ ------------------------------------

Key highlights of data accepted by AHA include:

Abstract Title Abstract Number/Presentation Details

------------------------------------------------------------------- --------------------------------------

Leqvio(R) (inclisiran)*

-------------------------------------------------------------------------------------------------------------

Effect Of Inclisiran-based Treatment Strategy, In Abstract #MP1723

Combination With Individually Optimized Statin Therapy, Moderated Digital Poster Presentation

On Quality Of Life And Muscle-related Pain vs. Standard November 9, 12:25 PM -- 12:30 PM CT

of Care: Exploratory Outcomes From The VICTORION-Difference

Study

------------------------------------------------------------------- --------------------------------------

VICTORION-INCEPTION: Adherence and Goal Attainment Abstract #MP1492

Data Support the Addition of Inclisiran to Background Moderated Digital Poster Presentation

Lipid-Lowering Therapy as a Lipid Management Strategy November 9, 10:18 AM -- 10:23 AM CT

Post-Acute Coronary Syndrome

------------------------------------------------------------------- --------------------------------------

VICTORION-INCEPTION: Consistent Low-Density Lipoprotein Abstract #Mo2111

Cholesterol Lowering With Inclisiran Following Acute Poster Presentation

Coronary Syndrome Independent of Index Lipid-Lowering November 10, 1:00 PM -- 2:00 PM CT

Therapy

------------------------------------------------------------------- --------------------------------------

Primary Results of the VICTORION-NOVEL (LDL-C maNagement Abstract #MP2380

PrOgram in Atherosclerotic Cardiovascular Disease Moderated Digital Poster Presentation

(ASCVD) Patients with Elevated LDL-C) Lipid Optimization November 10, 1:59 PM -- 2:04 PM CT

Multicenter Implementation Trial

------------------------------------------------------------------- --------------------------------------

Lipoprotein(a)

-------------------------------------------------------------------------------------------------------------

Overcoming Barriers For Research Participation In Abstract #MP913

Minority Patients In Lp(a)FRONTIERS EXPANSION: A Randomized, Moderated Digital Poster Presentation

Double-Blind, Placebo-Controlled, Multicenter Study November 8, 1:45 PM -- 1:50 PM CT

To Evaluate Efficacy And Safety Of Pelacarsen In U.S.

Black And Hispanic Patients with Elevated Lp(a) And

Established ASCVD

------------------------------------------------------------------- --------------------------------------

Elevated Lipoprotein(a) Is Independently Associated Abstract #MP376

With Greater Infarct Size, Especially in Premature Moderated Digital Poster Presentation

Atherosclerosis November 8, 9:50 AM -- 9:55 AM CT

------------------------------------------------------------------- --------------------------------------

Impact of Elevated Lipoprotein(a) on Cardiovascular Abstract #MP2201

Events in Patients with premature ASCVD: A Nationally Moderated Digital Poster Presentation

Representative Sample of US Medicare, Medicaid, and November 10, 2:20 PM -- 2:25 PM CT

Commercial Enrollees

------------------------------------------------------------------- --------------------------------------

Pacibekitug(**)

-------------------------------------------------------------------------------------------------------------

A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Abstract # MP1719

Study of Monthly or Quarterly Subcutaneous Administration Moderated Digital Poster Presentation

(MORE TO FOLLOW) Dow Jones Newswires

November 04, 2025 01:15 ET (06:15 GMT)